A shorter course of hypofractionated radiotherapy should be considered for patients with high-risk prostate cancer, say trialists, who report that efficacy and toxicity are similar to longer standard regimens.
Medscape Medical News
A shorter course of hypofractionated radiotherapy should be considered for patients with high-risk prostate cancer, say trialists, who report that efficacy and toxicity are similar to longer standard regimens.
Medscape Medical News
